An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma Review uri icon

Overview

MeSH Major

  • Fluorodeoxyglucose F18
  • Hodgkin Disease
  • Lymphoma, Large B-Cell, Diffuse
  • Positron-Emission Tomography
  • Radiopharmaceuticals

abstract

  • A significant amount of literature is available on treatment monitoring and response assessment in lymphoma using FDG-PET, yet confusion exists concerning the potential and limitations of FDG-PET for determining the presence of residual disease during chemotherapy (interim FDG-PET). This article reviews the role of interim FDG-PET in 3 important scenarios: untreated diffuse large B-cell lymphoma, untreated Hodgkin lymphoma, and relapsed or refractory aggressive lymphoma in transplant-eligible patients, and provides recommendations on the use of this imaging modality in these settings.

publication date

  • March 2010

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 20202464

Additional Document Info

start page

  • 347

end page

  • 52

volume

  • 8

number

  • 3